HER2-Positive Breast Cancer Archives - Oncology Nurse Advisor

HER2-Positive Breast Cancer

Tukysa Approved for Advanced Unresectable or Metastatic HER2-Positive Breast Cancer

The FDA has approved Tukysa (tucatinib; Seattle Genetics), in combination with trastuzumab and capecitabine, for treatment of adult patients with advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer, including patients with brain metastases, who have received 1 or more prior anti-HER2-based regimens in the metastatic setting.

Tucatinib Gets Priority Review for Locally Advanced or Metastatic HER2-Positive Breast Cancer

The FDA has accepted for Priority Review the New Drug Application (NDA) for tucatinib (Seattle Genetics), in combination with trastuzumab and capecitabine, for the treatment of patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received at least 3 prior HER2-directed agents separately or in combination, in the neoadjuvant, adjuvant or metastatic setting.

Next post in SABCS 2017